Status:

COMPLETED

Safety and Efficacy of Inhaled OligoG CF-5/20 for the Treatment Cystic Fibrosis

Lead Sponsor:

AlgiPharma AS

Collaborating Sponsors:

Smerud Medical Research International AS

Conditions:

Cystic Fibrosis

Eligibility:

MALE

18-65 years

Phase:

PHASE1

Brief Summary

Cystic fibrosis (CF) is a disease caused by a mutation in the gene that makes the cystic fibrosis transmembrane regulator protein. As a result mucus stagnation, obstruction and plugging take place in ...

Eligibility Criteria

Inclusion

  • Healthy, male subjects aged 18 to 65 years inclusive
  • Normal pulmonary function; i.e. FEV1 ≥ 80% of predicted (for age, sex, height and race) and FEV1/FVC ratio ≥ 0.7
  • Subject's pre -study physical examination, vital signs and electrocardiogram (ECG) are normal or do not show any clinically significant abnormalities as determined by the investigator
  • Subject's pre - study laboratory screen are normal or, if outside of the laboratory reference range, not considered clinically significant

Exclusion

  • History of any clinically relevant chronic respiratory disorder, including asthma
  • Current smoker or smoked within the last 12 months
  • History of significant drug or alcohol abuse (defined by the investigator). Subjects with a positive screen for alcohol or drugs of abuse at screening/admission will be excluded from participation in the study.
  • Subject who has inhaled any drug in the last 30 days prior to Day 1
  • Subject who has received one or more days of systemic pharmacological treatment in the 14 days immediately prior to Day 1
  • Participation in a New Chemical Entity clinical study within the previous 16 weeks or a marketed drug clinical study within the previous 12 weeks
  • Subjects with a clinically relevant history of significant hepatic, renal, endocrine, cardiac, nervous, psychiatric, gastrointestinal, pulmonary, haematological or metabolic disorder

Key Trial Info

Start Date :

September 1 2009

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

November 1 2009

Estimated Enrollment :

26 Patients enrolled

Trial Details

Trial ID

NCT00970346

Start Date

September 1 2009

End Date

November 1 2009

Last Update

March 23 2016

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Merthyr Tydfil, United Kingdom